Japanese
Home
About us
Business areas
Contact us
2024.11.13
Syros Pharmaceuticals Inc., announced Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression.
2024.08.14
Syros Pharmaceuticals Inc., has announced that it will no longer be enrolling new patients in its clinical trial for AML.
2024.04.10
FDA has granted Fast Track Designation to Tamibarotene for the treatment of Newly Diagnosed Unfit AML.
more info
